Targets › NADS
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Sep 2027.
Open in Phaseline: the race on NADS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Douglas Seals | Nicotinamide riboside NAD+ precursor that reverses age-related arterial dysfunction | NADS | Phase 2 | Hypertension | Sep 2027 |
Hypertension (1)
small molecule (1)
Douglas Seals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.